cilostazol has been researched along with Cerebral Ischemia in 95 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol, a phosphodiesterase III inhibitor, appears to be a promising agent for preventing cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage." | 9.41 | Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. ( Akhtar, IN; Beall, J; Bhatti, I; Broderick, JP; Cassarly, CN; Lodhi, A; Ma, X; Martin, RH; Qureshi, AI; Sharma, R; Suarez, JI; Thakkar, M, 2023) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 9.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia." | 9.24 | Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. ( Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Shin, DH, 2017) |
| "To perform an updated meta-analysis to comprehensively assess the efficacy and safety of cilostazol in preventing aneurysmal subarachnoid hemorrhage (SAH)-related secondary complications." | 9.22 | Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. ( Fu, X; Li, L; Qiu, H; Shi, P, 2022) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 9.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 9.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia." | 9.15 | Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011) |
| "Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome." | 9.15 | Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2011) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 9.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 9.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "gov were searched from inception to 25 September 2020, for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo, in patients with ischaemic stroke." | 9.12 | Cilostazol for secondary stroke prevention: systematic review and meta-analysis. ( Chan, BP; Leow, AS; Sharma, VK; Sia, CH; Tan, BY; Tan, CH; Wu, AG; Yeo, LL, 2021) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 9.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects." | 8.98 | Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. ( Desai, A; Ibrahim, M; Mohamed, W; Palla, M; Saber, H; Seraji-Bozorgzad, N, 2018) |
| " Stroke recurrence (including hemorrhagic and ischemic) with cilostazol use was 5." | 8.91 | Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis. ( Cao, L; Feng, H; Hu, R; Margaret, B; Tan, L; Yin, Y; Zhang, JH; Zhang, Y, 2015) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "Aspirin is widely used for secondary prevention after stroke." | 8.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| " Cilostazol (CLZ) has pleiotropic effects including neuroprotection in several ravaging central disorders; nonetheless, its potential role in transient central ischemic-induced allodynia and hyperalgesia has not been asserted before." | 8.12 | Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. ( Abdallah, DM; Mohammed, RA; Nassar, NN; Safar, MM; Zaki, OS, 2022) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 7.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| "The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated." | 7.96 | Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia. ( Liu, Y; Ma, XY; Mang, J; Shao, MY; Sun, Y; Wang, LM; Wei, AX; Xu, ZX, 2020) |
| "Although long-term treatment with the oral anticoagulant warfarin is widely used to prevent cardioembolic ischemic stroke, it has been reported that warfarin can exacerbate hemorrhagic transformation (HT) after cerebral ischemia." | 7.79 | Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice. ( Egashira, Y; Hara, H; Ito, H; Kitashoji, A; Mishiro, K; Shimazawa, M; Suzuki, Y; Tsuruma, K, 2013) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 7.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| " In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia." | 7.77 | Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. ( Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK, 2011) |
| "To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice." | 7.77 | [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice]. ( Jiang, LL; Li, Q; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP, 2011) |
| "Normobaric hyperoxia (NBO) and cilostazol (6-[4-(1-cyclohexy-1H-tetrazol-5-yl)butoxyl]-3,4-dihydro-2-(1H)-quinolinone) (a selective inhibitor of phosphodiesterase 3) have each been reported to exert neuroprotective effects against acute brain injury after cerebral ischemia in rodents." | 7.75 | Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. ( Hara, H; Hyakkoku, K; Iwama, T; Koumura, A; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2009) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 7.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "To evaluate whether delayed treatment with the antiplatelet agent cilostazol reduces the volume of infarction in the gray and white matter in a rodent model of permanent focal cerebral ischemia and to explore the mechanism of the neuroprotective effect in vivo." | 7.73 | Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. ( Fukunaga, M; Honda, F; Imai, H; Ishikawa, M; Kubota, C; Saito, N; Shimizu, T, 2006) |
| "Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) remains an important problem with a complex pathophysiology." | 7.01 | Association Between Spreading Depolarization and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Post Hoc Analysis of a Randomized Trial of the Effect of Cilostazol on Delayed Cerebral Ischemia. ( Inoue, T; Ishihara, H; Kawano, A; Kawano, R; Nomura, S; Oka, F; Sadahiro, H; Sugimoto, K; Suzuki, M, 2021) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 6.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| "Cilostazol, a phosphodiesterase III inhibitor, appears to be a promising agent for preventing cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage." | 5.41 | Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. ( Akhtar, IN; Beall, J; Bhatti, I; Broderick, JP; Cassarly, CN; Lodhi, A; Ma, X; Martin, RH; Qureshi, AI; Sharma, R; Suarez, JI; Thakkar, M, 2023) |
| "Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage." | 5.36 | The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. ( Hattori, K; Kajimura, M; Morikawa, T; Suematsu, M, 2010) |
| "In the present study, cerebral ischemia was induced by a 10 min transient bilateral common carotid artery occlusion in rats combined with arterial blood pressure lowering to 37-42 mm Hg during occlusion." | 5.35 | Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats. ( Hong, KW; Kim, CD; Lee, JH; Lee, WS; Park, SY; Shin, HK, 2009) |
| "Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression." | 5.35 | Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. ( Fujimoto, S; Kaneko, S; Kashiwaba, T; Shirasaka, T; Tokuda, K; Yamauchi, T; Yoshidumi, T; Yoshimoto, T, 2009) |
| "Oral treatment with cilostazol 30 mg/kg two times at 5 min and 4 h significantly suppressed the hemispheric lesion area and volumes when detected by ADC, T2 images and histology, but 3 and 10 mg/kg cilostazol were without effect." | 5.32 | Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats--an MRI study. ( Fukunaga, M; Hong, KW; Hosokawa, T; Ishikawa, M; Koga, K; Lee, JH; Lee, YK; Miyakoda, G; Mori, T, 2003) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 5.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| " The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage-Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of cilostazol, probucol, or both on IMT in patients with stroke." | 5.24 | Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study. ( Kim, YJ; Kwon, SU; Lee, J; Seo, WK, 2017) |
| "In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia." | 5.24 | Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. ( Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Shin, DH, 2017) |
| "To perform an updated meta-analysis to comprehensively assess the efficacy and safety of cilostazol in preventing aneurysmal subarachnoid hemorrhage (SAH)-related secondary complications." | 5.22 | Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies. ( Fu, X; Li, L; Qiu, H; Shi, P, 2022) |
| "Nimodipine and cilostazol are likely the most effective treatments in preventing morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage." | 5.22 | Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials. ( Ahmadvand, S; Amin-Hanjani, S; Dayyani, M; Grotta, JC; Guyatt, GH; Sadeghirad, B; Wang, Y; Zabihyan, S, 2022) |
| " This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function." | 5.22 | Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage. ( Hong, KS; Kwon, SU; Lee, J; Lee, JS; Oh, MS; Yu, KH, 2016) |
| "PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage was designed to compare cilostazol and aspirin and to assess the effect of adding probucol, a lipid-lowering and anti-oxidative agent, in patients at high risk of haemorrhagic stroke." | 5.20 | Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. ( Hong, KS; Kim, BJ; Kwon, SU; Lee, JY, 2015) |
| "We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke." | 5.19 | Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 5.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 5.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome." | 5.15 | Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2011) |
| "Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia." | 5.15 | Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 5.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 5.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| " Cilostazol is useful for the prevention of the recurrence of vascular events in patients with lacunar infarction, and is probably effective in high-risk patients with diabetes and/or hypertension." | 5.13 | Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. ( Fukuuchi, Y; Gotoh, F; Hirai, S; Itoh, E; Matsuda, T; Nishimaru, K; Ohashi, Y; Otomo, E; Sawada, T; Shinohara, Y; Terashi, A; Tohgi, H; Yamaguchi, T, 2008) |
| "gov were searched from inception to 25 September 2020, for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo, in patients with ischaemic stroke." | 5.12 | Cilostazol for secondary stroke prevention: systematic review and meta-analysis. ( Chan, BP; Leow, AS; Sharma, VK; Sia, CH; Tan, BY; Tan, CH; Wu, AG; Yeo, LL, 2021) |
| "Cilostazol was effective and safe to reduce incidences of severe angiographic vasospasm, symptomatic vasospasm, new cerebral infarction and poor outcome in patients after aneurysmal subarachnoid hemorrhage." | 5.05 | Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. ( Li, H; Ma, L; Qian, W; Shan, T; Xie, X; You, C; Zhang, T, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "Cilostazol, a selective inhibitor of phosphodiesterase 3, may reduce symptomatic vasospasm and improve outcome in patients with aneurysmal subarachnoid hemorrhage considering its anti-platelet and vasodilatory effects." | 4.98 | Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. ( Desai, A; Ibrahim, M; Mohamed, W; Palla, M; Saber, H; Seraji-Bozorgzad, N, 2018) |
| " Stroke recurrence (including hemorrhagic and ischemic) with cilostazol use was 5." | 4.91 | Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis. ( Cao, L; Feng, H; Hu, R; Margaret, B; Tan, L; Yin, Y; Zhang, JH; Zhang, Y, 2015) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "Aspirin is widely used for secondary prevention after stroke." | 4.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| " Cilostazol (CLZ) has pleiotropic effects including neuroprotection in several ravaging central disorders; nonetheless, its potential role in transient central ischemic-induced allodynia and hyperalgesia has not been asserted before." | 4.12 | Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories. ( Abdallah, DM; Mohammed, RA; Nassar, NN; Safar, MM; Zaki, OS, 2022) |
| "The influence of cilostazol on learning and memory, and cyclin D1 expression in the cerebral cortex of rats with chronic cerebral ischemia were investigated." | 3.96 | Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia. ( Liu, Y; Ma, XY; Mang, J; Shao, MY; Sun, Y; Wang, LM; Wei, AX; Xu, ZX, 2020) |
| "It is unclear whether cilostazol instead of aspirin in combination with clopidogrel could prevent in-stent thrombosis in patients with a history of gout undergoing vertebral artery origin stenting." | 3.96 | Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports. ( Ji, RJ; Lin, YJ; Yuan, HW, 2020) |
| " We performed cognitive behavioral tests, including the water maze task, odor discrimination task, and novel object test; histological investigation of neuroinflammation, oligodendrocytes, myelin basic protein, and nodal or paranodal proteins at the nodes of Ranvier; and serial diffusion tensor imaging." | 3.83 | Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion. ( Back, DB; Choi, BR; Choi, DH; Han, JS; Han, SH; Kang, CH; Kim, BR; Kim, DH; Kim, HY; Kwon, KJ; Lee, J; Moon, WJ; Shin, CY, 2016) |
| " He was thought to have had an embolic stroke and was initially treated with warfarin." | 3.80 | Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014) |
| "Although long-term treatment with the oral anticoagulant warfarin is widely used to prevent cardioembolic ischemic stroke, it has been reported that warfarin can exacerbate hemorrhagic transformation (HT) after cerebral ischemia." | 3.79 | Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice. ( Egashira, Y; Hara, H; Ito, H; Kitashoji, A; Mishiro, K; Shimazawa, M; Suzuki, Y; Tsuruma, K, 2013) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 3.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| "To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice." | 3.77 | [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice]. ( Jiang, LL; Li, Q; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP, 2011) |
| " The aim of the present study is to investigate the effects of cilostazol and aspirin on endothelial nitric oxide synthase (eNOS) phosphorylation in the cerebral cortex, endothelial function, and infarct size after brain ischemia in spontaneously hypertensive rats (SHR)." | 3.77 | Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. ( Kawamura, M; Kitagawa, K; Omura-Matsuoka, E; Oyama, N; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2011) |
| " In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia." | 3.77 | Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. ( Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK, 2011) |
| "Normobaric hyperoxia (NBO) and cilostazol (6-[4-(1-cyclohexy-1H-tetrazol-5-yl)butoxyl]-3,4-dihydro-2-(1H)-quinolinone) (a selective inhibitor of phosphodiesterase 3) have each been reported to exert neuroprotective effects against acute brain injury after cerebral ischemia in rodents." | 3.75 | Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. ( Hara, H; Hyakkoku, K; Iwama, T; Koumura, A; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2009) |
| "Cilostazol, a selective inhibitor of phosphodiesterase 3, exerts neuroprotective effects on acute brain injury after cerebral ischemia in rats." | 3.74 | Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. ( Fang, SH; Liu, LY; Shi, WZ; Wang, ML; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP; Zhou, Y, 2007) |
| "To evaluate whether delayed treatment with the antiplatelet agent cilostazol reduces the volume of infarction in the gray and white matter in a rodent model of permanent focal cerebral ischemia and to explore the mechanism of the neuroprotective effect in vivo." | 3.73 | Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. ( Fukunaga, M; Honda, F; Imai, H; Ishikawa, M; Kubota, C; Saito, N; Shimizu, T, 2006) |
| "We have previously reported that the phosphodiesterase inhibitor cilostazol, an antiplatelet agent, is effective and safe for secondary prevention of recurrent cerebral infarction (Cilostazol Stroke Prevention Study; CSPS)." | 3.73 | Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. ( Shinohara, Y, 2006) |
| "Cerebral small vessel disease is characterized by progressive cerebral white matter changes (WMCs)." | 3.11 | Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. ( Cho, SJ; Choi, SH; Choi, YH; Han, HJ; Jeong, JH; Kim, BC; Kim, EJ; Kim, JH; Kim, S; Lee, JH; Lee, JM; Na, DL; Oh, MS; Park, G; Park, HY; Park, KC; Park, KH; Park, KW; Park, SA; Shim, Y; Yoon, B; Yoon, SJ; Youn, YC, 2022) |
| "Delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (SAH) remains an important problem with a complex pathophysiology." | 3.01 | Association Between Spreading Depolarization and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Post Hoc Analysis of a Randomized Trial of the Effect of Cilostazol on Delayed Cerebral Ischemia. ( Inoue, T; Ishihara, H; Kawano, A; Kawano, R; Nomura, S; Oka, F; Sadahiro, H; Sugimoto, K; Suzuki, M, 2021) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 2.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| "The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction and ischemic stroke at 6 months after PCI." | 2.76 | Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-. ( Bae, JH; Bae, JW; Chae, IH; Cho, MC; Kim, HS; Lee, SP; Park, KW; Rha, SW; Suh, JW, 2011) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| "Stroke is the second cause of mortality worldwide, and intravenous administration of tissue plasminogen activator (t-PA) within 3 h of symptom onset is the only treatment proven effective for re-establishment of cerebral blood flow following acute ischemic stroke." | 2.47 | Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke. ( Hara, H; Shimazawa, M, 2011) |
| "Intracranial arterial stenosis (IAS) is the cause of about 10% of all ischemic strokes in the United States, but may account for about 40% of strokes in some populations." | 2.47 | Current management of symptomatic intracranial stenosis. ( Kasner, SE; Taylor, RA; Weigele, JB, 2011) |
| "Cilostazol was developed as a selective inhibitor of cyclic nucleotide phosphodiesterase 3 (PDE3)." | 2.43 | Cilostazol: therapeutic potential against focal cerebral ischemic damage. ( Hong, KW; Kima, KY; Lee, JH; Lee, WS; Park, SY, 2006) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Methods- Focal cerebral ischemia was induced by transient middle cerebral artery occlusion in 6- to 8-week-old male C57Bl/6 wild-type mice receiving substance V or vehicle 1 hour after ischemia induction." | 1.51 | Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function. ( Bieber, M; Kleinschnitz, C; Kraft, P; Kumar, GJ; Nieswandt, B; Pham, M; Schuhmann, MK; Stoll, G; Vaidya, JR; Volz, J, 2019) |
| "Cilostazol treatment reduced the impairment in working memory and white matter function after hypoperfusion." | 1.46 | Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion. ( Binnie, M; Duncombe, J; Horsburgh, K; Ihara, M; Jansen, M; Kalaria, RN; Kitamura, A; Koudelka, J; Lennen, R; Manso, Y; Marshall, I; Searcy, J; Webster, S, 2017) |
| "Cilostazol(CTL) is a phosphodiesterase inhibitor, which has been widely used as anti-platelet agent." | 1.43 | Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1. ( Li, M; Liu, F; Liu, P; Ma, JY; Mei, XY; Miu, JC; Qi, DS; Qu, R; Tao, JH; Wang, M; Zhang, F; Zhang, LQ; Zhang, SC, 2016) |
| "Cilostazol treatment significantly reduced the percentage of 8-OHdG-positive neurons (65." | 1.42 | Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia. ( Abumiya, T; Hokari, M; Houkin, K; Kazumata, K; Kuroda, S; Nakayama, N; Shichinohe, H; Tan, C, 2015) |
| "Sildenafil failed to prevent CCH-induced retrograde amnesia, but it reduced hippocampal cell death." | 1.42 | Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats. ( Bacarin, CC; de Oliveira, JN; de Oliveira, RM; Ferreira, ED; Godinho, J; Milani, H; Zaghi, GG, 2015) |
| "Oral treatment with cilostazol (30 mg/kg) significantly increased plasma leakage." | 1.36 | The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum. ( Hattori, K; Kajimura, M; Morikawa, T; Suematsu, M, 2010) |
| "Vascular dementia is caused by blockage of blood supply to the brain, which causes ischemia and subsequent lesions primarily in the white matter, a key characteristic of the disease." | 1.36 | Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain. ( Hattori, N; Miyamoto, N; Mochizuki, H; Mori, H; Onodera, M; Shimura, H; Tanaka, R; Urabe, T; Watanabe, T, 2010) |
| "Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size." | 1.36 | Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010) |
| "Mice subjected to 6-h middle cerebral artery occlusion were treated with delayed tPA alone at 6 h, with combined tPA plus cilostazol at 6 h, or with vehicle at 6 h." | 1.36 | Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. ( Chen, H; Fujiwara, Y; Hara, H; Ishiguro, M; Iwama, T; Izuta, H; Mishiro, K; Satoh, M; Shimazawa, M; Tsuruma, K; Yoshimura, S, 2010) |
| "In the present study, cerebral ischemia was induced by a 10 min transient bilateral common carotid artery occlusion in rats combined with arterial blood pressure lowering to 37-42 mm Hg during occlusion." | 1.35 | Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats. ( Hong, KW; Kim, CD; Lee, JH; Lee, WS; Park, SY; Shin, HK, 2009) |
| "Cilostazol is an antiplatelet aggregation inhibitor drug associated with increased cerebral blood flow and inflammation suppression." | 1.35 | Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. ( Fujimoto, S; Kaneko, S; Kashiwaba, T; Shirasaka, T; Tokuda, K; Yamauchi, T; Yoshidumi, T; Yoshimoto, T, 2009) |
| "Post-treatment with cilostazol (60 mg kg(-1) day(-1)) strongly suppressed not only elevated activation of astroglia and microglia but also diminished oligodendrocytes following chronic cerebral hypoperfusion." | 1.33 | Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. ( Hong, KW; Kim, CD; Kim, KY; Lee, JH; Lee, WS; Park, SY; Shin, YW; Sung, SM, 2006) |
| "Cilostazol (30 mg/kg) was intraperitoneally administered at 12 h before, 1 h before, and just after MCA occlusion." | 1.33 | Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2. ( Hara, H; Hozumi, I; Inuzuka, T; Morimoto, N; Nagase, H; Shimazawa, M; Wakida, K, 2006) |
| "Oral treatment with cilostazol 30 mg/kg two times at 5 min and 4 h significantly suppressed the hemispheric lesion area and volumes when detected by ADC, T2 images and histology, but 3 and 10 mg/kg cilostazol were without effect." | 1.32 | Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats--an MRI study. ( Fukunaga, M; Hong, KW; Hosokawa, T; Ishikawa, M; Koga, K; Lee, JH; Lee, YK; Miyakoda, G; Mori, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.05) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (23.16) | 29.6817 |
| 2010's | 56 (58.95) | 24.3611 |
| 2020's | 16 (16.84) | 2.80 |
| Authors | Studies |
|---|---|
| Kawano, A | 2 |
| Sugimoto, K | 2 |
| Nomura, S | 2 |
| Inoue, T | 2 |
| Kawano, R | 2 |
| Oka, F | 2 |
| Sadahiro, H | 2 |
| Ishihara, H | 2 |
| Suzuki, M | 2 |
| Kim, BC | 1 |
| Youn, YC | 1 |
| Jeong, JH | 1 |
| Han, HJ | 1 |
| Kim, JH | 3 |
| Lee, JH | 11 |
| Park, KH | 1 |
| Park, KW | 4 |
| Kim, EJ | 1 |
| Oh, MS | 2 |
| Shim, Y | 1 |
| Lee, JM | 1 |
| Choi, YH | 1 |
| Park, G | 1 |
| Kim, S | 2 |
| Park, HY | 1 |
| Yoon, B | 1 |
| Yoon, SJ | 1 |
| Cho, SJ | 1 |
| Park, KC | 1 |
| Na, DL | 1 |
| Park, SA | 1 |
| Choi, SH | 1 |
| Li, L | 1 |
| Fu, X | 1 |
| Qiu, H | 2 |
| Shi, P | 1 |
| Dayyani, M | 1 |
| Sadeghirad, B | 1 |
| Grotta, JC | 1 |
| Zabihyan, S | 1 |
| Ahmadvand, S | 1 |
| Wang, Y | 1 |
| Guyatt, GH | 1 |
| Amin-Hanjani, S | 1 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Shirai, Y | 1 |
| Toi, S | 1 |
| Adachi, U | 1 |
| Tsutsumi, Y | 1 |
| Kitagawa, K | 2 |
| Zaki, OS | 1 |
| Nassar, NN | 1 |
| Abdallah, DM | 1 |
| Safar, MM | 1 |
| Mohammed, RA | 1 |
| Bath, PM | 1 |
| Mhlanga, I | 1 |
| Woodhouse, LJ | 1 |
| Doubal, F | 1 |
| Oatey, K | 1 |
| Montgomery, AA | 1 |
| Wardlaw, JM | 1 |
| Aspide, R | 3 |
| Castioni, CA | 3 |
| Qureshi, AI | 5 |
| Akhtar, IN | 3 |
| Ma, X | 3 |
| Lodhi, A | 3 |
| Bhatti, I | 3 |
| Beall, J | 3 |
| Broderick, JP | 3 |
| Cassarly, CN | 3 |
| Martin, RH | 3 |
| Sharma, R | 3 |
| Thakkar, M | 3 |
| Suarez, JI | 3 |
| Kim, SM | 1 |
| Jung, JM | 3 |
| Kim, BJ | 4 |
| Lee, JS | 5 |
| Kwon, SU | 7 |
| Park, JH | 2 |
| Kim, YJ | 3 |
| Hong, KS | 4 |
| Wong, LKS | 2 |
| Yu, S | 2 |
| Hwang, YH | 2 |
| Lee, J | 5 |
| Rha, JH | 2 |
| Heo, SH | 2 |
| Ahn, SH | 2 |
| Seo, WK | 3 |
| Park, JM | 2 |
| Kwon, JH | 2 |
| Sohn, SI | 2 |
| Navarro, JC | 2 |
| Kim, HY | 3 |
| Kim, EG | 1 |
| Cha, JK | 2 |
| Park, MS | 1 |
| Nam, HS | 1 |
| Kang, DW | 3 |
| Wei, AX | 1 |
| Shao, MY | 1 |
| Liu, Y | 1 |
| Sun, Y | 1 |
| Wang, LM | 1 |
| Ma, XY | 1 |
| Mang, J | 1 |
| Xu, ZX | 1 |
| Dawley, T | 1 |
| Claus, CF | 1 |
| Tong, D | 1 |
| Rajamand, S | 1 |
| Sigler, D | 1 |
| Bahoura, M | 1 |
| Garmo, L | 1 |
| Soo, TM | 1 |
| Kelkar, P | 1 |
| Richards, B | 1 |
| Yuan, HW | 1 |
| Lin, YJ | 1 |
| Ji, RJ | 1 |
| Tan, CH | 1 |
| Wu, AG | 1 |
| Sia, CH | 1 |
| Leow, AS | 1 |
| Chan, BP | 1 |
| Sharma, VK | 1 |
| Yeo, LL | 1 |
| Tan, BY | 1 |
| Kitamura, A | 2 |
| Manso, Y | 1 |
| Duncombe, J | 1 |
| Searcy, J | 1 |
| Koudelka, J | 1 |
| Binnie, M | 1 |
| Webster, S | 1 |
| Lennen, R | 1 |
| Jansen, M | 1 |
| Marshall, I | 1 |
| Ihara, M | 2 |
| Kalaria, RN | 1 |
| Horsburgh, K | 1 |
| Lee, SJ | 2 |
| Choi, MH | 1 |
| Lee, SE | 1 |
| Shin, DH | 1 |
| Hong, JM | 1 |
| Lee, EJ | 1 |
| Saber, H | 1 |
| Desai, A | 1 |
| Palla, M | 1 |
| Mohamed, W | 1 |
| Seraji-Bozorgzad, N | 1 |
| Ibrahim, M | 1 |
| Wu, Z | 1 |
| Liu, AF | 1 |
| Zhou, J | 1 |
| Zhang, Y | 2 |
| Wang, K | 1 |
| Li, C | 2 |
| Jiang, WJ | 1 |
| Chiba, T | 1 |
| Setta, K | 1 |
| Shimada, Y | 1 |
| Yoshida, J | 1 |
| Fujimoto, K | 1 |
| Tsutsui, S | 1 |
| Yoshida, K | 1 |
| Kobayashi, M | 1 |
| Kubo, Y | 1 |
| Fujiwara, S | 2 |
| Terasaki, K | 1 |
| Ogasawara, K | 1 |
| Shirao, S | 1 |
| Suehiro, E | 1 |
| Shinoyama, M | 1 |
| Oku, T | 1 |
| Maruta, Y | 1 |
| Hirayama, Y | 1 |
| Hiyoshi, K | 1 |
| Kiyohira, M | 1 |
| Yoneda, H | 1 |
| Okazaki, K | 1 |
| Dreier, JP | 1 |
| Bieber, M | 1 |
| Schuhmann, MK | 1 |
| Volz, J | 1 |
| Kumar, GJ | 1 |
| Vaidya, JR | 1 |
| Nieswandt, B | 1 |
| Pham, M | 1 |
| Stoll, G | 1 |
| Kleinschnitz, C | 1 |
| Kraft, P | 1 |
| Shan, T | 1 |
| Zhang, T | 1 |
| Qian, W | 1 |
| Ma, L | 1 |
| Li, H | 1 |
| You, C | 1 |
| Xie, X | 1 |
| Park, SY | 8 |
| Lee, YS | 2 |
| Heo, HJ | 1 |
| Shin, HK | 5 |
| Lee, WS | 8 |
| Hong, KW | 11 |
| Kim, CD | 7 |
| Hill, MD | 1 |
| Benavente, OR | 1 |
| Toyoda, K | 2 |
| Uchiyama, S | 3 |
| Yamaguchi, T | 3 |
| Easton, JD | 2 |
| Kimura, K | 2 |
| Hoshino, H | 2 |
| Sakai, N | 1 |
| Okada, Y | 1 |
| Tanaka, K | 2 |
| Origasa, H | 2 |
| Naritomi, H | 2 |
| Houkin, K | 2 |
| Yamaguchi, K | 1 |
| Isobe, M | 1 |
| Minematsu, K | 2 |
| Maruyama, H | 1 |
| Fukuoka, T | 1 |
| Deguchi, I | 1 |
| Ohe, Y | 1 |
| Nagoya, H | 1 |
| Kato, Y | 1 |
| Horiuchi, Y | 1 |
| Hayashi, T | 1 |
| Tanahashi, N | 1 |
| Kitashoji, A | 1 |
| Egashira, Y | 1 |
| Mishiro, K | 2 |
| Suzuki, Y | 1 |
| Ito, H | 3 |
| Tsuruma, K | 3 |
| Shimazawa, M | 6 |
| Hara, H | 7 |
| Nakagawa, I | 1 |
| Wada, T | 1 |
| Park, HS | 1 |
| Nishimura, F | 1 |
| Yamada, S | 1 |
| Nakagawa, H | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Qian, Y | 1 |
| Bi, Q | 1 |
| Kwon, HM | 1 |
| Bae, HJ | 1 |
| Chen, J | 1 |
| Meng, H | 1 |
| Xu, L | 1 |
| Liu, J | 1 |
| Kong, D | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 1 |
| Eikelboom, JW | 1 |
| Bae, SS | 3 |
| Shin, YI | 1 |
| Choi, BT | 2 |
| Shichinohe, H | 1 |
| Tan, C | 1 |
| Abumiya, T | 1 |
| Nakayama, N | 1 |
| Kazumata, K | 1 |
| Hokari, M | 1 |
| Kuroda, S | 1 |
| Godinho, J | 1 |
| de Oliveira, JN | 1 |
| Ferreira, ED | 1 |
| Zaghi, GG | 1 |
| Bacarin, CC | 1 |
| de Oliveira, RM | 1 |
| Milani, H | 1 |
| Tan, L | 1 |
| Margaret, B | 1 |
| Zhang, JH | 1 |
| Hu, R | 1 |
| Yin, Y | 1 |
| Cao, L | 1 |
| Feng, H | 1 |
| Lee, JY | 1 |
| Choi, BR | 1 |
| Kim, DH | 1 |
| Back, DB | 1 |
| Kang, CH | 1 |
| Moon, WJ | 1 |
| Han, JS | 1 |
| Choi, DH | 1 |
| Kwon, KJ | 1 |
| Shin, CY | 1 |
| Kim, BR | 1 |
| Han, SH | 1 |
| Wang, W | 1 |
| Zhang, L | 1 |
| Liu, W | 1 |
| Zhu, Q | 1 |
| Lan, Q | 1 |
| Zhao, J | 1 |
| Yu, KH | 1 |
| Qi, DS | 1 |
| Tao, JH | 1 |
| Zhang, LQ | 1 |
| Li, M | 1 |
| Wang, M | 1 |
| Qu, R | 1 |
| Zhang, SC | 1 |
| Liu, P | 1 |
| Liu, F | 1 |
| Miu, JC | 1 |
| Ma, JY | 1 |
| Mei, XY | 1 |
| Zhang, F | 1 |
| Shinohara, Y | 2 |
| Gotoh, F | 2 |
| Tohgi, H | 1 |
| Hirai, S | 1 |
| Terashi, A | 1 |
| Fukuuchi, Y | 2 |
| Otomo, E | 1 |
| Itoh, E | 1 |
| Matsuda, T | 1 |
| Sawada, T | 1 |
| Nishimaru, K | 1 |
| Ohashi, Y | 1 |
| Yuzawa, I | 1 |
| Yamada, M | 1 |
| Fujii, K | 1 |
| Nonaka, Y | 2 |
| Koumura, A | 1 |
| Hyakkoku, K | 1 |
| Yoshimura, S | 3 |
| Iwama, T | 3 |
| Miyamoto, N | 2 |
| Tanaka, R | 3 |
| Zhang, N | 2 |
| Shimura, H | 2 |
| Onodera, M | 2 |
| Mochizuki, H | 2 |
| Hattori, N | 2 |
| Urabe, T | 3 |
| Yoshimoto, T | 1 |
| Shirasaka, T | 1 |
| Fujimoto, S | 1 |
| Yoshidumi, T | 1 |
| Yamauchi, T | 1 |
| Tokuda, K | 1 |
| Kaneko, S | 1 |
| Kashiwaba, T | 1 |
| Gomez, CR | 1 |
| Hashimoto, A | 1 |
| Matsumoto, Y | 2 |
| Yao, H | 1 |
| Miyakoda, G | 2 |
| Watanabe, T | 2 |
| Mori, H | 1 |
| Ha, SW | 1 |
| Guo, JJ | 1 |
| Xu, E | 2 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
| Morikawa, T | 1 |
| Hattori, K | 1 |
| Kajimura, M | 1 |
| Suematsu, M | 1 |
| Lee, SP | 3 |
| Suh, JW | 3 |
| Lee, HY | 2 |
| Kang, HJ | 2 |
| Koo, BK | 2 |
| Chae, IH | 3 |
| Choi, DJ | 2 |
| Rha, SW | 3 |
| Bae, JW | 3 |
| Cho, MC | 3 |
| Kwon, TG | 2 |
| Bae, JH | 3 |
| Kim, HS | 3 |
| Ishiguro, M | 2 |
| Fujiwara, Y | 1 |
| Chen, H | 1 |
| Izuta, H | 1 |
| Satoh, M | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Kamal, AK | 2 |
| Naqvi, I | 1 |
| Husain, MR | 1 |
| Khealani, BA | 1 |
| Lee, DH | 1 |
| Lee, HR | 1 |
| Kim, EK | 1 |
| Rhim, BY | 3 |
| Matsumoto, S | 1 |
| Shimodozono, M | 1 |
| Miyata, R | 1 |
| Kawahira, K | 1 |
| Khan, M | 1 |
| Zhang, Q | 2 |
| Ye, YL | 2 |
| Li, Q | 1 |
| Zhang, WP | 2 |
| Jiang, LL | 1 |
| Wei, EQ | 2 |
| Yu, YP | 2 |
| Park, SH | 1 |
| Kim, YD | 1 |
| Park, KP | 1 |
| Al-Qudah, ZA | 1 |
| Hassan, AE | 1 |
| Taylor, RA | 1 |
| Weigele, JB | 1 |
| Kasner, SE | 1 |
| Ueno, H | 1 |
| Koyama, H | 1 |
| Mima, Y | 1 |
| Fukumoto, S | 1 |
| Tanaka, S | 1 |
| Shoji, T | 2 |
| Emoto, M | 1 |
| Nishizawa, Y | 1 |
| Inaba, M | 1 |
| Oyama, N | 1 |
| Yagita, Y | 1 |
| Kawamura, M | 1 |
| Sugiyama, Y | 1 |
| Terasaki, Y | 1 |
| Omura-Matsuoka, E | 1 |
| Sasaki, T | 1 |
| Nakamura, T | 1 |
| Tsuruta, S | 1 |
| Hase, Y | 1 |
| Okamoto, Y | 1 |
| Fujita, Y | 1 |
| Nakabayashi, H | 1 |
| Maki, T | 1 |
| Washida, K | 1 |
| Takahashi, R | 1 |
| Fujita, K | 1 |
| Komatsu, Y | 1 |
| Sato, N | 1 |
| Higuchi, O | 1 |
| Kujiraoka, Y | 1 |
| Kamezaki, T | 1 |
| Suzuki, K | 1 |
| Matsumura, A | 1 |
| Johkura, K | 1 |
| Yoshida, TN | 1 |
| Kudo, Y | 1 |
| Nakae, Y | 1 |
| Momoo, T | 1 |
| Kuroiwa, Y | 1 |
| Naganuma, M | 1 |
| Isoda, K | 1 |
| Nishi, S | 1 |
| Ito, K | 1 |
| Hirano, T | 1 |
| Kondo, R | 1 |
| Furui, E | 1 |
| Itabashi, R | 1 |
| Sato, S | 1 |
| Yazawa, Y | 1 |
| Shimizu, H | 1 |
| Takahashi, A | 1 |
| Tominaga, T | 1 |
| Kim, KY | 2 |
| Lee, YK | 2 |
| Ishikawa, M | 2 |
| Koga, K | 1 |
| Fukunaga, M | 2 |
| Mori, T | 1 |
| Hosokawa, T | 1 |
| Honda, F | 1 |
| Imai, H | 1 |
| Kubota, C | 1 |
| Shimizu, T | 1 |
| Saito, N | 1 |
| Kima, KY | 1 |
| Shin, YW | 2 |
| Sung, SM | 1 |
| Liu, M | 1 |
| Mizuno, Y | 1 |
| Wakida, K | 1 |
| Morimoto, N | 1 |
| Hozumi, I | 1 |
| Nagase, H | 1 |
| Inuzuka, T | 1 |
| Shi, WZ | 1 |
| Wang, ML | 1 |
| Zhou, Y | 1 |
| Fang, SH | 1 |
| Liu, LY | 1 |
| Huang, Y | 1 |
| Cheng, Y | 1 |
| Wu, J | 1 |
| Li, Y | 1 |
| Hong, Z | 1 |
| Li, Z | 1 |
| Zhang, W | 1 |
| Ding, M | 1 |
| Gao, X | 1 |
| Fan, D | 1 |
| Zeng, J | 1 |
| Wong, K | 1 |
| Lu, C | 1 |
| Xiao, J | 1 |
| Yao, C | 1 |
| Hankey, GJ | 1 |
| Amano, T | 1 |
| Uematsu, D | 1 |
| Kawamura, J | 1 |
| Yamawaki, T | 1 |
| Itoh, N | 1 |
| Obara, K | 1 |
| Muramatsu, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial[NCT04148105] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| The Effect of Cilostazol Compared to Aspirin on Endothelial Function Measured by Flow Mediated Dilatation in Acute Cerebral Ischemia Patients[NCT03116269] | Phase 4 | 80 participants (Actual) | Interventional | 2012-03-01 | Completed | ||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| A Randomized, Prospective, Placebo-controlled Double-blind, Pilot Study on the Effect of Cilostazol for 4 Weeks in Patients With Chronic Tinnitus[NCT01378650] | 50 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
18 reviews available for cilostazol and Cerebral Ischemia
| Article | Year |
|---|---|
Effects of cilostazol treatment for patients with aneurysmal subarachnoid hemorrhage: A meta-analysis of 14 studies.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Treatment Outcome; | 2022 |
Prophylactic Therapies for Morbidity and Mortality After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Network Meta-Analysis of Randomized Trials.
Topics: Adult; Brain Ischemia; Cilostazol; Humans; Magnesium; Morbidity; Network Meta-Analysis; Nicardipine; | 2022 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Effect of Cilostazol in Animal Models of Cerebral Ischemia and Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Cilostazol; Likelihood Functions; Models, Animal; Suba | 2023 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Cilostazol for secondary stroke prevention: systematic review and meta-analysis.
Topics: Brain Ischemia; Cilostazol; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Randomized Control | 2021 |
Efficacy of Cilostazol in Prevention of Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis.
Topics: Aged; Brain Ischemia; Chi-Square Distribution; Cilostazol; Female; Humans; Male; Middle Aged; Odds R | 2018 |
Effectiveness and feasibility of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.
Topics: Brain Ischemia; Cardiovascular Agents; Cerebral Infarction; Cilostazol; Humans; Intracranial Aneurys | 2020 |
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc | 2013 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis.
Topics: Aged; Brain Ischemia; Cilostazol; Databases, Factual; Female; Fibrinolytic Agents; Humans; Male; Mid | 2015 |
Antiplatelet Agents for the Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack: A Network Meta-Analysis.
Topics: Asian People; Brain Ischemia; Cilostazol; Humans; Ischemic Attack, Transient; Network Meta-Analysis; | 2016 |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma | 2011 |
[Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].
Topics: Animals; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cyclic AMP; Disease Models, Animal; Endoth | 2011 |
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: protective effects of antiplatelet agents against stroke.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Endothelium, Vascular; Humans; Intracrania | 2011 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clop | 2011 |
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Patholog | 2011 |
Cilostazol: therapeutic potential against focal cerebral ischemic damage.
Topics: Animals; Brain Ischemia; Cilostazol; Humans; Neuroprotective Agents; Phosphodiesterase Inhibitors; S | 2006 |
29 trials available for cilostazol and Cerebral Ischemia
| Article | Year |
|---|---|
Association Between Spreading Depolarization and Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: Post Hoc Analysis of a Randomized Trial of the Effect of Cilostazol on Delayed Cerebral Ischemia.
Topics: Brain Ischemia; Cilostazol; Humans; Microcirculation; Prospective Studies; Subarachnoid Hemorrhage; | 2021 |
Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Double | 2022 |
Cilostazol improves endothelial function in patients with ischemic stroke: A randomized controlled single-center study with flow-mediated dilation technique.
Topics: Brain Ischemia; Cilostazol; Dilatation; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; St | 2022 |
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850).
Topics: Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Female; Humans; Middle Aged; Prospective | 2023 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Efficacy and safety of cilostazol-nimodipine combined therapy on delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage: a prospective, randomised, double-blinded, placebo-controlled trial protocol.
Topics: Brain Ischemia; Cilostazol; Humans; Multicenter Studies as Topic; Nimodipine; Prospective Studies; Q | 2020 |
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study.
Topics: Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Common; Carotid Inti | 2017 |
Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique.
Topics: Adult; Aged; Arginine; Aspirin; Brain Ischemia; C-Reactive Protein; Cilostazol; Dilatation; Double-B | 2017 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Cilostazol decreases duration of spreading depolarization and spreading ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Aged; Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Cortical Spreading Depressio | 2018 |
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; | 2019 |
Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke.
Topics: Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clopidogrel; | 2013 |
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub | 2014 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; | 2015 |
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
Topics: Adult; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cognition Disorder | 2016 |
Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Cilostazol; Diabetes Complications; Double-Blind Method; | 2008 |
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
Topics: Aspirin; Bleeding Time; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Resistance; Drug Thera | 2010 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients.
Topics: Adult; Aged; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation; Cilostazol; Female; Hem | 2011 |
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial.
Topics: Aged; Aspirin; Brain Ischemia; Cholesterol, LDL; Cilostazol; Diabetes Mellitus; Endothelium, Vascula | 2011 |
Inhibitory interaction between calcium channel blocker and clopidogrel. -Efficacy of cilostazol to overcome it-.
Topics: Aged; Brain Ischemia; Calcium Channel Blockers; Cilostazol; Clopidogrel; Death; Drug Antagonism; Dru | 2011 |
Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2012 |
Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combinati | 2011 |
Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Brain Stem; Cerebellum; Cerebrovascular Circulatio | 2012 |
Effect of cilostazol in the treatment of acute ischemic stroke in the lenticulostriate artery territory.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Therapy, Combination; | 2013 |
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female; | 2008 |
48 other studies available for cilostazol and Cerebral Ischemia
| Article | Year |
|---|---|
Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1/Glutamate and Akt/Dopamine/BDNF/Nrf2 Trajectories.
Topics: Animals; Brain Ischemia; Brain-Derived Neurotrophic Factor; Carrier Proteins; Cerebral Cortex; Cilos | 2022 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Cilostazol in Cerebral Ischemia and Subarachnoid Hemorrhage: A Promising Agent as Prevention.
Topics: Brain Ischemia; Cerebral Infarction; Cilostazol; Humans; Subarachnoid Hemorrhage; Tetrazoles | 2023 |
Influence of Cilostazol on Changes in Cyclin D1 Expression in Cerebral Cortex of Rats with Chronic Cerebral Ischemia.
Topics: Animals; Brain Ischemia; Cerebral Cortex; Chronic Disease; Cilostazol; Cyclin D1; Disease Models, An | 2020 |
Cilostazol plus clopidogrel in the prevention of in-stent stenosis after vertebral artery origin stenting in gout patients: three case reports.
Topics: Aged; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination; | 2020 |
Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion.
Topics: Animals; Brain Ischemia; Cell Adhesion Molecules; Cilostazol; Disease Models, Animal; Dose-Response | 2017 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Comparison of Effects between Clopidogrel and Cilostazol on Cerebral Perfusion in Nonsurgical Adult Patients with Symptomatically Ischemic Moyamoya Disease: Subanalysis of a Prospective Cohort.
Topics: Adult; Blood Flow Velocity; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Clopidogrel; Dr | 2018 |
Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.
Topics: Animals; Blood Platelets; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Disease Models, Animal; M | 2019 |
Augmented improvement of cognition and memory by aripiprazole add-on for cilostazol treatment in the chronic cerebral hypoperfusion mouse model.
Topics: Animals; Aripiprazole; Brain; Brain Ischemia; Carotid Stenosis; Cilostazol; Cognition; Cognitive Dys | 2019 |
The uncertain role for phosphodiesterase inhibitors in stroke prevention.
Topics: Brain Ischemia; Cilostazol; Humans; Japan; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibi | 2019 |
Cilostazol ameliorates warfarin-induced hemorrhagic transformation after cerebral ischemia in mice.
Topics: Animals; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Endothelium, Vascular; Mal | 2013 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag | 2014 |
Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Brain Injuries; Brain Ischemia; CD11b Antigen; Cerebr | 2014 |
Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Brain; Brain Ischemia; Cilostazol; CREB-Binding Protein; Deoxy | 2015 |
Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats.
Topics: Aging; Amnesia, Retrograde; Animals; Brain Ischemia; Carotid Artery Diseases; Carotid Artery, Intern | 2015 |
Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion.
Topics: Animals; Behavior, Animal; Brain Ischemia; Carotid Stenosis; Chronic Disease; Cilostazol; Cognition; | 2016 |
Neuroprotection of Cilostazol against ischemia/reperfusion-induced cognitive deficits through inhibiting JNK3/caspase-3 by enhancing Akt1.
Topics: Animals; Apoptosis; Brain Ischemia; Caspase 3; Cilostazol; Cognition Disorders; Disease Models, Anim | 2016 |
An oral administration of cilostazol before focal ischemia reduces the infarct volume with delayed cerebral blood flow increase in rats.
Topics: Administration, Oral; Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Infarction, | 2008 |
Cilostazol preserves CA1 hippocampus and enhances generation of immature neuroblasts in dentate gyrus after transient forebrain ischemia in rats.
Topics: Analysis of Variance; Animals; Brain Ischemia; Bromodeoxyuridine; Carotid Artery Diseases; Cell Surv | 2009 |
Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.
Topics: Animals; Brain Ischemia; Cilostazol; Combined Modality Therapy; Hyperoxia; Male; Mice; Neurons; Neur | 2009 |
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.
Topics: Animals; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Disease Models | 2009 |
Crucial role for Ser133-phosphorylated form of cyclic AMP-responsive element binding protein signaling in the differentiation and survival of neural progenitors under chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Brain Ischemia; Carotid Stenosis; Cerebral Ventricles; Cerebrovascular Circulati | 2009 |
Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage.
Topics: Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebral Infarction; Cilostazol; Disability | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog | 2010 |
Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain.
Topics: Adult; Animals; Brain; Brain Ischemia; Cell Differentiation; Cilostazol; Dementia, Vascular; Enzyme | 2010 |
The effects of cilostazol on tissue oxygenation upon an ischemic-reperfusion injury in the mouse cerebrum.
Topics: Animals; Brain Ischemia; Cerebrum; Cilostazol; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Ox | 2010 |
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Cyclic Nucleotide Phosphodiest | 2010 |
Cilostazol enhances integrin-dependent homing of progenitor cells by activation of cAMP-dependent protein kinase in synergy with Epac1.
Topics: Animals; Brain Ischemia; Cells, Cultured; Chemotaxis; Cilostazol; Cyclic AMP-Dependent Protein Kinas | 2011 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
[Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice].
Topics: Administration, Intranasal; Animals; Brain; Brain Ischemia; Cilostazol; Disease Models, Animal; Infa | 2011 |
Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia.
Topics: Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Drug Therapy, Combination; Hyperch | 2011 |
Cilostazol in patients with ischemic stroke.
Topics: Animals; Brain Ischemia; Cilostazol; Disease Models, Animal; Humans; Phosphodiesterase 3 Inhibitors; | 2011 |
Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Cilostazol; Endothel | 2011 |
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Topics: Administration, Oral; Animals; Antigens, CD; Brain; Brain Edema; Brain Ischemia; Calcium-Binding Pro | 2012 |
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic | 2014 |
Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats.
Topics: Animals; Blood-Brain Barrier; Blotting, Western; Brain Ischemia; Casein Kinase II; Chromosomes; Cilo | 2004 |
Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats--an MRI study.
Topics: Animals; Brain; Brain Edema; Brain Ischemia; Cilostazol; Magnetic Resonance Imaging; Male; Rats; Rat | 2003 |
Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia.
Topics: Animals; Axons; Brain; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Disease Models, Anim | 2006 |
Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion.
Topics: Administration, Oral; Animals; Apoptosis; Brain; Brain Ischemia; Caspase 3; Caspases; Cilostazol; Di | 2006 |
Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Chronic Disease; Cilostazol; Cyclic AMP Response Element- | 2006 |
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Chronic Disease; Cilostazol; Female; Follow-Up Studies; H | 2006 |
Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2.
Topics: Animals; Brain Ischemia; Cerebral Cortex; Cilostazol; Enzyme Induction; Immunohistochemistry; Infarc | 2006 |
Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Brain; Brain Ischemia; Cilostazol; Cyclic Nucleotide P | 2007 |
Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Brain Ischemia; Caspase 3; Cerebral Infarction; Chemot | 2007 |
Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats.
Topics: Animals; Behavior, Animal; Brain; Brain Ischemia; Choline O-Acetyltransferase; Cilostazol; Cognition | 2007 |
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Data Interpretation, Statistical; Dose-Res | 2008 |
Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.
Topics: Animals; Azoles; Blood Pressure; Brain Ischemia; Cats; Cerebral Arteries; Cerebrovascular Circulatio | 1989 |